文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

黑色素瘤中放疗联合BRAFV600E抑制的序贯依赖性交叉耐药

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.
PubMed 文献 · Eur J Cancer · 2019-02-02

该研究通过临床前模型和65例IV期黑色素瘤脑转移患者的回顾性随访数据,探讨BRAFV600E抑制剂(BRAFi)与放疗联合治疗的序贯依赖性交叉耐药。临床前模型显示先BRAFi后放疗较反向序贯的肿瘤复发率更高;回顾性数据显示MAPK抑制剂预治疗患者颅内转移灶局部缓解持续时间较未预治疗者缩短。JARID1B/KDM5B被鉴定为BRAFi与放疗间交叉耐药的细胞标志物。

要点

  • 先BRAFi后放疗较反向序贯的肿瘤复发率更高(临床前模型)。
  • MAPK抑制剂预治疗的脑转移患者局部缓解持续时间较未预治疗者缩短。
  • JARID1B高表达细胞在先行BRAFi较先行放疗时更常见。

核心结论

  • MAPK抑制与放疗间交叉耐药的水平取决于治疗顺序。
  • JARID1B可能代表一种新的跨治疗耐药标志物。

研究设计与样本

  • 临床前模型研究结合65例IV期黑色素瘤脑转移患者的回顾性随访数据。

主要发现

  • 临床前模型显示先BRAFi后放疗较反向序贯的肿瘤复发率更高。
  • 65例IV期黑色素瘤脑转移患者的回顾性随访数据证实,MAPK抑制剂预治疗的颅内转移灶较未预治疗者局部缓解持续时间缩短。
  • JARID1B高表达细胞在先行BRAFi较先行放疗时更常见。
  • JARID1B通过转录调控控制细胞周期、DNA修复和细胞死亡的基因促进细胞存活。

关键数值与推荐

  • JARID1B/KDM5B被鉴定为BRAFi与放疗间交叉耐药的细胞标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Treatment of patients with metastatic melanoma is hampered by drug-resistance and often requires combination with radiotherapy as last-resort option. However, also after radiotherapy, clinical relapses are common. METHODS & RESULTS: Our preclinical models indicated a higher rate of tumour relapse when melanoma cells were first treated with BRAFV600E inhibition (BRAFi) followed by radiotherapy as compared to the reverse sequence. Accordingly, retrospective follow-up data from 65 stage-IV melanoma patients with irradiated melanoma brain metastases confirmed a shortened duration of local response of mitogen-activated protein kinase (MAPK)-inhibitor-pretreated compared with MAPK-inhibitor-naïve intracranial metastases. On the molecular level, we identified JARID1B/KDM5B as a cellular marker for cross-resistance between BRAFi and radiotherapy. JARID1Bhigh cells appeared more frequently under upfront BRAFi as compared with upfront radiation. JARID1B favours cell survival by transcriptional regulation of genes controlling cell cycle, DNA repair and cell death. CONCLUSION: The level of cross-resistance between combined MAPK inhibition and radiotherapy is dependent on the treatment sequence. JARID1B may represent a novel therapy-overarching resistance marker.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Shannan B, Matschke J, Chauvistré H, et al. Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma. Eur J Cancer. 2019. PMID: 30721788. doi:10.1016/j.ejca.2018.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。